Predictive Oncology (POAI) announced today the company has successfully developed 3D organoid models exclusively for Labcorp (LH), a global leader of innovative and comprehensive laboratory services. As part of an ongoing agreement, Predictive Oncology recently developed two distinct and unique 3D liver toxicity models exclusively for Labcorp, including a human and rat model. Both models represent the liver microenvironment and can be used for the evaluation of both drug metabolism and liver toxicity related to drugs.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on POAI:
- Predictive Oncology Faces Nasdaq Delisting Notice
- Predictive Oncology says court denies Renovaro motion for expedited trial
- Renovaro announces expedited trial on suit to enforce Predictive Oncology merger
- Predictive Oncology moves to leverage biobank using AI
- Predictive Oncology issued shareholder letter